Enhanced Phase 2 dose-optimization study designed to accelerate development and support a streamlined Phase 3 programMELBOURNE, Australia and NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- Incannex ...
Good day, everyone, and welcome to Pfizer Pflash, a spotlight on the PD-1 VEGF bispecific PF-4404 clinical development strategy. Today's call is being recorded. At this time, I would like to turn the ...
Q4 2025 Management View CEO Punit Dhillon outlined recent progress for nimacimab, highlighting the transition from promising early signals to a robust development case. Dhillon stated, "CBeyond ...
SHELTON, CONNECTICUT / ACCESS Newswire / October 15, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), reports that an analyst research report was published on the Company that explains ...
Company reports encouraging monotherapy expansion data in platinum-resistant ovarian cancer and initiates first combination study with standard-of-care chemotherapies in Q1 2026 Timothy Bowler, M.D., ...
NEW YORK, March 10, 2026 /PRNewswire/ -- Sperm testing & freezing company Legacy today announced the appointment of Dr. Scott Lundy, MD, PhD, as Chief Medical Officer. A nationally recognized expert ...
Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, ...
Over the past decade, the economics of drug development have become increasingly unforgiving. Global pharmaceutical R&D spending now exceeds $300 billion annually, yet bringing a new therapy to market ...
SHELTON, CONNECTICUT / ACCESS Newswire / October 15, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that an analyst research report was published on the Company that explains ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results